Can sulfasalazine therapy induce or exacerbate Wegener's granulomatosis?

N H A M Denissen, J G P Peters, R Masereeuw, P Barrera

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Sulfasalazine (SSZ) can induce serological and clinical autoimmune reactions but the occurrence of SSZ-related Wegener's granulomatosis (WG) has not been reported before. We describe two patients with rheumatoid factor (RF)-positive rheumatoid arthritis (RA) who developed biopsy-proven WG with serious organ involvement during SSZ therapy. The pathogenetic mechanism that explains the relationship between SSZ and the occurrence of a de novo anti-neutrophil cytoplasmic antibody (ANCA)-related vasculitis or a flare is discussed. We propose that WG can be a rare complication of SSZ therapy and that this, like other autoimmune adverse events of this drug, is mediated by SSZ-induced apoptosis.

Original languageEnglish
Pages (from-to)72-4
Number of pages3
JournalScandinavian Journal of Rheumatology
Volume37
Issue number1
DOIs
Publication statusPublished - 15 Jan 2008

Keywords

  • Adult
  • Aged
  • Antirheumatic Agents
  • C-Reactive Protein
  • Cyclophosphamide
  • Disease Progression
  • Glucocorticoids
  • Granulomatosis with Polyangiitis
  • Humans
  • Methylprednisolone
  • Sulfasalazine

Fingerprint

Dive into the research topics of 'Can sulfasalazine therapy induce or exacerbate Wegener's granulomatosis?'. Together they form a unique fingerprint.

Cite this